Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $28 | $35 | $29 | $39 |
| Short-Term Investments | $697 | $387 | $276 | $369 |
| Receivables | $1 | $5 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $21 | $5 | $12 | $2 |
| Total Curr. Assets | $747 | $432 | $318 | $411 |
| Property Plant & Equip (Net) | $8 | $7 | $8 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $27 | $27 | $27 | $27 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $10 | $0 | $0 | $0 |
| Total NC Assets | $45 | $34 | $35 | $34 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $792 | $466 | $353 | $445 |
| Liabilities | – | – | – | – |
| Payables | $3 | $3 | $3 | $1 |
| Short-Term Debt | $1 | $2 | $1 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $35 | $26 | $14 | $14 |
| Total Curr. Liab. | $40 | $31 | $19 | $17 |
| LT Debt | $2 | $1 | $3 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $3 | $4 | $5 | $7 |
| Total NC Liab. | $6 | $5 | $8 | $9 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $4 | $1 | $4 | $3 |
| Total Liabilities | $45 | $36 | $27 | $25 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,555 | -$1,397 | -$1,256 | -$1,144 |
| AOCI | $3 | $3 | $1 | $2 |
| Other Equity | $2,299 | $1,823 | $1,581 | $1,561 |
| Total Equity | $747 | $429 | $326 | $419 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $792 | $466 | $353 | $445 |
| Net Debt | -$25 | -$32 | -$25 | -$36 |